Fractyl Health, Inc. Research and Development Expense
Fractyl Health, Inc. (GUTS) reported Research and Development Expense of $13.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Fractyl Health, Inc. research and development expense for the quarter ending 2026-06-30 was $13.81M, a 34.70% decline year-over-year.
- Fractyl Health, Inc. research and development expense for the quarter ending 2026-03-31 was $15.60M, a 19.74% decline year-over-year.
- Fractyl Health, Inc. research and development expense for the quarter ending 2025-12-31 was $16.49M, a 18.68% decline year-over-year.
- Fractyl Health, Inc. research and development expense for the quarter ending 2025-09-30 was $17.46M, a 8.14% decline year-over-year.
- Fractyl Health, Inc. research and development expense for fiscal 2025 was $74.54M, a 5.77% increase from fiscal 2024.
- Fractyl Health, Inc. research and development expense for fiscal 2024 was $70.47M, a 85.26% increase from fiscal 2023.
- Fractyl Health, Inc. research and development expense for fiscal 2023 was $38.04M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.81M 10-Q · filed 2026-08-10 | $29.41M 10-Q · filed 2026-08-10 | $45.90M derived: sum of 3 quarters · filed 2026-08-10 | $63.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $15.60M 10-Q · filed 2026-05-12 | $32.09M derived: sum of 2 quarters · filed 2026-05-12 | $49.55M derived: sum of 3 quarters · filed 2026-05-12 | $70.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $33.95M derived: sum of 2 quarters · filed 2026-03-24 | $55.10M derived: sum of 3 quarters · filed 2026-08-10 | $74.54M 10-K · filed 2026-03-24 |
| 2025-09-30 | $17.46M 10-Q · filed 2025-11-12 | $38.61M derived: sum of 2 quarters · filed 2026-08-10 | $58.04M 10-Q · filed 2025-11-12 | $78.32M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $21.15M 10-Q · filed 2026-08-10 | $40.59M 10-Q · filed 2026-08-10 | $60.87M derived: sum of 3 quarters · filed 2026-08-10 | $79.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $19.43M 10-Q · filed 2026-05-12 | $39.72M derived: sum of 2 quarters · filed 2026-05-12 | $58.72M derived: sum of 3 quarters · filed 2026-05-12 | $75.48M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $39.28M derived: sum of 2 quarters · filed 2026-03-24 | $56.05M derived: sum of 3 quarters · filed 2026-03-24 | $70.47M 10-K · filed 2026-03-24 |
| 2024-09-30 | $19.00M 10-Q · filed 2025-11-12 | $35.77M derived: sum of 2 quarters · filed 2025-11-12 | $50.19M 10-Q · filed 2025-11-12 | $60.36M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $16.76M 10-Q · filed 2025-08-12 | $31.19M 10-Q · filed 2025-08-12 | $41.35M derived: sum of 3 quarters · filed 2025-08-12 | $50.73M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $14.42M 10-Q · filed 2025-05-13 | $24.59M derived: sum of 2 quarters · filed 2025-05-13 | $33.97M derived: sum of 3 quarters · filed 2025-05-13 | $43.11M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $10.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $19.55M derived: sum of 2 quarters · filed 2025-03-03 | $28.69M derived: sum of 3 quarters · filed 2025-03-03 | $38.04M 10-K · filed 2025-03-03 |
| 2023-09-30 | $9.38M 10-Q · filed 2024-11-12 | $18.52M derived: sum of 2 quarters · filed 2024-11-12 | $27.87M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $9.14M 10-Q · filed 2024-08-14 | $18.49M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $9.35M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |